Takeaways from the 2024 JPM Healthcare Conference

The rain was falling in San Francisco last week. But somehow inside the JPM Morgan Healthcare conference, it was sunny, or at least a lot sunnier than the gloom and doom of 2023 when biotech was in a freefall.

So is the industry in for a rosy 2024 or will it be back to negativity again soon?

TOPICS
(01:35) Optimistic views on the Healthcare industry
(02:04) The pros and cons of interest rates on Biotech
(03:49) Analysis of the probable long and short-term effects of weight-loss drugs
(05:01) Application and lack of application in AI in Obesity and Heart diseases
(07:10) The role of Nvidia in drug production and AI
(09:34) Eroom's law and the effects on Drug production
(10:09) Artificial Intelligence’s effects on Drug development
(15:36) Initial Public Offering as a mark of lifting market optimism
(16:11) The optimism and pessimism of IPO in Biotech
(19:22) Addressing Neurological and Psychiatric Diseases in Technology

🎙️⚕️ABOUT CARETALK
CareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (President U.S. Healthcare and EVP, Walgreens Boots Alliance) and David Williams (President, Health Business Group) as they debate the latest in US healthcare news, business and policy.

📥 GET IN TOUCH
Become a CareTalk Podcast sponsor: https://www.caretalkpodcast.com/work-...
Guest appearance requests: https://www.caretalkpodcast.com/conta...
Visit us at https://www.caretalkpodcast.com

📲 FOLLOW
Spotify: https://open.spotify.com/show/2GTYhbN....
Apple Podcasts: https://podcasts.apple.com/us/podcast....
Follow us on LinkedIn:   / caretalk-podcast  

🗞️ Subscribe to our newsletter: https://www.caretalkpodcast.com/newsl...
🛒 Shop for official CareTalk merch: https://www.caretalkpodcast.com/categ...

⚙️ Produced by Grippi Media: https://www.grippimedia.com

#healthcare #healthcarepodcast #healthcarebusiness #healthcarepolicy #healthinsurance #healthcaretechnology #healthcarefinance #caretalk #biotechnology #biotech #ipo #jpmorgan